LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma
Latest Information Update: 03 Aug 2022
At a glance
- Drugs Nintedanib (Primary) ; Cisplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Registrational; Therapeutic Use
- Acronyms LUME-Meso
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 03 Aug 2022 This trial has been completed in Denmark, according to European Clinical Trials Database record.
- 30 Jun 2019 Trial has been completed in Croatia, according to European Clinical Trials Database record.
- 15 Mar 2019 Status changed from completed to discontinued.